Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novastan argatroban: Phase III data; approvable

TXB presented data from a Phase III study of 304 patients with heparin-induced

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE